The study involved four major activities to estimate the current size of the Therapeutic Drug Monitoring Market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Both top-down and bottom-up approaches were employed to estimate the complete market size.Expected Revenue Surge: The Global Therapeutic Drug Monitoring Market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025GROWTH OPPORTUNITY: Increasing adoption in the treatment of autoimmune diseases;TDM is being used for Methotrexate (MTX), a folic acid analog used as a therapeutic agent for the treatment of autoimmune disease.

MTX was initially used at low doses to treat chronic autoimmune disorders such as RA and Crohn’s disease.

However, nearly 40% of patients with RA do not respond to MTX or show clinical improvement.

TDM for MTX targets measures the level of MTX-PGs in the blood cells of patients with RA and correlates these levels with response to therapy, which shows its potential applications in the area.Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=155350443Market Segmentation in Detailed:Based on Technology;The therapeutic drug monitoring market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive agents, and other drugs.

According MarketsandMarkets Research – The Global Therapeutic Drug Monitoring Market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025.Market Segmentation in Depth:On the basis of product, the therapeutic drug monitoring market is segmented into consumables and equipment.

In 2019, consumables segment accounted for the largest market share, primarily due to the repeat purchases of kits and reagents and the increasing number of immunoassay tests being performed across the globe.On the basis of technology, the TDM Market is segmented into immunoassays and chromatography-MS.

The immunoassays segment accounted for the largest share of this market in 2019, mainly due to the increasing incidence of chronic and infectious diseases and technological innovation.On the basis of technology, the therapeutic drug monitoring market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive agents, and other drugs.

Antiepileptics are the most commonly monitored class of drugs due to the high complexity and heterogeneity of epilepsy, lack of biological markers or specific clinical signs aside from the frequency of seizures to assess treatment efficacy or toxicity, and the highly complex pharmacokinetics of these drugs.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155350443“North America is expected to hold the highest share in 2020”The large share of the therapeutic drug monitoring market in North America can be attributed to the increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region, coupled with initiatives taken by different government associations,Key Market Players;The major players operating in the TDM Market include Abbott Laboratories (U.S.), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories (U.S.), bioMérieux (France), BÜHLMANN Laboratories (Switzerland), SEKISUI MEDICAL (Japan), Randox Laboratories (Ireland), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (United Kingdom), ARK Diagnostics, Inc. (U.S.), Chromsystems Instruments & Chemicals GmbH (Germany), Grifols (Spain), Exagen Inc. (U.S.), Theradiag (France)Abbott Laboratories (US);Abbott has a strong presence in the US and seeks to further enhance its geographical presence by strengthening its business operations in emerging and high-growth markets.

The company’s extensive R activities for product development and ongoing clinical trials for newly developed medicines are expected to drive the growth of its market share in the coming years.

In 2019, Abbott invested USD 2.4 billion in R activities, of which USD 533 million was invested for the development of technologically advanced diagnostic products.Thermo Fisher Scientific (US);Thermo Fisher Scientific accounted for the second-largest share of almost 13.5% of the global market in 2019.

The Therapeutic Drug Monitoring Market is projected to reach to reach $1.63 billion, at a CAGR of 5.9% during the forecast period.The growth of this market is majorly driven by the rising number of organ transplant procedures and the use of TDM in traditional anticancer therapies.

However, the lack of financial provisions for the clinical interpretation of TDM results is expected to restrain the growth of this market during the forecast period.Market Dynamics:Driver:Use of TDM in traditional anticancer therapies;TDM provides valuable guidance for the dose adjustment of antibiotics, immunosuppressants, antiepileptics, and other drugs.

However, its use in traditional anticancer therapies has been limited.

The requirement of multiple blood samples to adequately define the systemic exposure of anticancer drugs is the major issue encountered while testing for anticancer therapies.Drugs in blood samples have a short elimination half-life and are given by intermittent intravenous injections; this makes the entire monitoring process difficult to analyze.

Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many cytotoxic agents, including imatinib, sunitinib, rituximab, and cetuximab.

Although current evidence is not sufficient to make TDM a compulsory practice, investigations with encouraging results will have a practical place in the clinical care of patients with cancer.

The study involved four major activities to estimate the current size of the therapeutic drug monitoring market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.According MarketsandMarkets Research - The Global Therapeutic Drug Monitoring Market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025.The Key Factors Who will Drives the Market Growth?- Importance of TDM in organ transplant procedures- Use of TDM across various therapeutic fields- Increasing preference for precision medicine- Growing focus on R activities related to TDM- Technological advancements- Increasing adoption in the treatment of autoimmune diseasesGROWTH OPPORTUNITY: Increasing adoption in the treatment of autoimmune diseasesTDM is being used for Methotrexate (MTX), a folic acid analog used as a therapeutic agent for the treatment of autoimmune disease.

MTX was initially used at low doses to treat chronic autoimmune disorders such as RA and Crohn’s disease.

Owing to its low cost, safety, effectiveness, and clinical history, MTX is the first-line treatment for RA.

However, nearly 40% of patients with RA do not respond to MTX or show clinical improvement.

TDM for MTX targets measures the level of MTX-PGs in the blood cells of patients with RA and correlates these levels with response to therapy, which shows its potential applications in the area.Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=155350443Leading Key Players in the Worldwide Industry:The major players operating in the therapeutic drug monitoring market include Abbott Laboratories (U.S.), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories (U.S.), bioMérieux (France), BÜHLMANN Laboratories (Switzerland), SEKISUI MEDICAL (Japan), Randox Laboratories (Ireland), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (United Kingdom), ARK Diagnostics, Inc. (U.S.)Geographical Regions Mapped in Report:On the basis of region, the therapeutic drug monitoring market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The scope of the study includes the various consumables and equipment’s used to perform therapeutic drug monitoring assays What the Market Looks Like?

Predicted to grow at a CAGR of 5.9% during the forecast period, the Global Therapeutic Drug Monitoring Market is estimated to reach USD 1.63 billion by the end of 2023.

Asia Pacific is expected to grow at the highest CAGR during the forecast period Based on product, the global market is segmented into consumables and equipment.

This growth can be attributed to the requirement of repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases.

The immunoassays segment is expected to account for the largest share of this market in 2018, mainly due to the increasing incidence of chronic and infectious diseases and technological innovation.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155350443 What Drives the Market?

According to the new market research report “Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User – Global Forecast to 2025″, published by MarketsandMarkets™, the Therapeutic Drug Monitoring Market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025.Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155350443The TDM Market growth is largely driven by factors such as the rising number of organ transplant procedures, the use of TDM across various therapeutic fields, the increasing preference for precision medicine, a growing focus on R related to TDM, and technological advancements in immunoassay instruments.

Increasing adoption in the treatment of autoimmune diseases is expected to provide a wide range of growth opportunities for players in the market.Consumables is expected to hold the largest share of the therapeutic drug monitoring market in 2020On the basis of product, the market is segmented into equipment and consumables.

In 2019, consumables segment accounted for the largest market share, primarily due to the repeat purchases of kits and reagents and the increasing number of immunoassay tests being performed across the globe.Browse in-depth TOC on “Therapeutic Drug Monitoring Market“288 – Tables35 – Figures241 – PagesImmunoassays is expected to hold the largest share of the market in 2020Based on technology, the TDM Market is segmented into immunoassays and chromatography-MS.

In 2019, immunoassays segment accounted for the largest market share, due to the increasing incidence of chronic and infectious diseases and technological innovation.Antiepileptic drugs is expected to hold the largest share of the therapeutic drug monitoring market in 2020On the basis of class of drug, the market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive agents, and other drugs.

During 2019, antiepileptic drugs held the largest share among the class of drug due to the high complexity and heterogeneity of epilepsy, lack of biological markers or specific clinical signs aside from the frequency of seizures to assess treatment efficacy or toxicity, and the highly complex pharmacokinetics of these drugs.Hospital laboratories segment commanded the largest share of the TDM Market in 2019By end user, the market is segmented into hospital laboratories, commercial & private laboratories, and other end users.

Hospital laboratories accounted for the largest share of the market in 2019.

Major players in the Therapeutic Drug Monitoring Market were identified through secondary research and their market presence was studied through primary and secondary research.

Secondary research included the study of the annual and financial reports of top market players, white papers, medical journals, certified publications, articles from recognized authors, directories, databases such as WHO, OECD, American Association for Clinical Chemistry (AACC), European Federation of Pharmaceutical Industries and Associations (EFPIA), International Trade Association, NCBI, and National Health Service (NHS).The Global Therapeutic Drug Monitoring Market is projected to reach USD 1.63 billion in 2023 from USD 1.23 billion in 2018, at a CAGR of 5.9%According to the new market research report "Therapeutic Drug Monitoring Market by Product (Consumable, Equipment (Immunoassay analyzer)), Technology (Fluorescence Immunoassay, Radioimmunoassay, GCMS), Class of drugs (Antibiotics, Bronchodilators), End User (Hospital Lab) - Global Forecast to 2023", published by MarketsandMarkets™.The growth of this market is majorly driven by the rising number of organ transplant procedures and the use of TDM in traditional anticancer therapies.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155350443 Therapeutic Drug Monitoring Market Segmentation: On the basis of product, the global market is segmented into consumables and equipment.

The consumables segment is expected to grow at the highest CAGR during the forecast period.

This growth can be attributed to the requirement of repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases.On the basis of technology, the global market is segmented into immunoassays and chromatography-MS.

The immunoassays segment is expected to account for the largest share of this market in 2018, mainly due to the increasing incidence of chronic and infectious diseases and technological innovation.Asia Pacific is expected to grow at the highest CAGR during the forecast periodThe APAC market is projected to register the highest growth during the forecast period.

Growth in this region can be attributed to the huge demand for better healthcare services; increasing incidence of chronic and infectious diseases; rapid development in healthcare infrastructure in developing countries such as India, China, and South Korea; growing healthcare research investments in this region; and increasing per capita income of the middle-class population.Read a Press-Release on “Therapeutic Drug Monitoring Market”:https://www.marketsandmarkets.com/PressReleases/therapeutic-drug-monitoring.aspMajor Leading Key Players in the Therapeutic Drug Monitoring Market - The key players operating in the TDM Market are F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), and Abbott (US).

[141 Pages Report] The Therapeutic Drug Monitoring Market is projected to reach to reach USD 1.63 billion, at a CAGR of 5.9% during the forecast period.Market DynamicsDriver:Use of TDM in traditional anticancer therapiesTDM provides valuable guidance for the dose adjustment of antibiotics, immunosuppressants, antiepileptics, and other drugs.

However, its use in traditional anticancer therapies has been limited.

The requirement of multiple blood samples to adequately define the systemic exposure of anticancer drugs is the major issue encountered while testing for anticancer therapies.Drugs in blood samples have a short elimination half-life and are given by intermittent intravenous injections; this makes the entire monitoring process difficult to analyze.

Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many cytotoxic agents, including imatinib, sunitinib, rituximab, and cetuximab.

Although current evidence is not sufficient to make TDM a compulsory practice, investigations with encouraging results will have a practical place in the clinical care of patients with cancer.

With the increasing incidence of cancer and focus on reducing the adverse effects of drugs, the monitoring of antineoplastic drugs is expected to gain more importance in the treatment of cancer.Browse 145 market data Tables and 23 Figures spread through 141 Pages and in-depth TOC – Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155350443  Based on product, the consumables segment is expected to grow at the highest CAGR during the forecast periodOn the basis of product, the global therapeutic drug monitoring market is segmented into consumables and equipment.